SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Fishman Sari

(Last) (First) (Middle)
C/O CAN-FITE BIOPHARMA LTD.
26 BEN GURION STREET

(Street)
RAMAT GAN L3 5257346

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
Can-Fite BioPharma Ltd. [ CANF ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP Business Development
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options to Purchase Ordinary Shares(1)(2) 07/24/2017 04/23/2027 Ordinary Shares 26(2) 3,537.03(3) D
Options to Purchase Ordinary Shares(1)(2) 03/28/2017 12/28/2027 Ordinary Shares 50(2) 2,427.24(4) D
Options to Purchase Ordinary Shares(1)(2) 01/07/2019 01/07/2029 Ordinary Shares 40(2) 2,264.01(5) D
Options to Purchase Ordinary Shares(1)(2) 08/27/2020 05/27/2030 Ordinary Shares 333(2) 241.47(6) D
Options to Purchase Ordinary Shares(1)(2) 04/13/2021 04/13/2031 Ordinary Shares 500(2) 247.36(7) D
Options to Purchase Ordinary Shares(1)(8) 07/17/2022 07/16/2032 Ordinary Shares 500(8) 241.47(8) D
Options to Purchase Ordinary Shares(1)(9) 08/01/2023 04/30/2033 Ordinary Shares 1,666(9) 25.21(9) D
Options to Purchase Ordinary Shares(1)(10) 05/07/2024 05/07/2034 Ordinary Shares 1,666(10) 26.56(10) D
Options to Purchase Ordinary Shares(1)(11) 07/29/2025 04/29/2035 Ordinary Shares 1,666(11) 17.39(11) D
Explanation of Responses:
1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.
2. These options are fully vested and exercisable as of the date hereof.
3. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 10,986, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
4. The exercise price of this option, originally denominated in NIS in the amount of NIS 7,539, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
5. The exercise price of this option, originally denominated in NIS in the amount of NIS 7,032, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
6. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
7. The exercise price of this option, originally denominated in NIS in the amount of NIS 768.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
8. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 437 options are vested, and the remaining 63 options vest in two equal quarterly installments beginning 04/17/2026 and ending 07/17/2026 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
9. The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,145 options are vested, and the remaining 521 options vest in five equal quarterly installments beginning 04/01/2026 and ending 04/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
10. The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 728 options are vested, and the remaining 938 options vest in nine equal quarterly installments beginning 05/07/2026 and ending 05/07/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
11. The exercise price of this option, originally denominated in NIS in the amount of NIS 54, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 312 options are vested, and the remaining 1,354 options vest in thirteen equal quarterly installments beginning 04/29/2026 and ending 04/29/2029 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
/s/ Sari Fishman 03/18/2026
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.